Illumina vs Bionano Genomics Which Outperforms?

Illumina and Bionano Genomics are two prominent companies in the genomics industry, both offering groundbreaking technologies and services that are revolutionizing the field of genetic research. Illumina's portfolio includes sequencers and array technologies, while Bionano Genomics focuses on optical genome mapping. Investors are closely watching these two companies as they continue to innovate and compete in the rapidly growing genomics market. Understanding the key differences and potential risks and rewards of investing in Illumina versus Bionano Genomics stocks is crucial for making informed investment decisions.

Illumina or Bionano Genomics?

When comparing Illumina and Bionano Genomics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and Bionano Genomics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while Bionano Genomics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Bionano Genomics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.43 and Bionano Genomics's P/E ratio at -0.15. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 10.76 while Bionano Genomics's P/B ratio is 0.42.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while Bionano Genomics's is -0.94%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and Bionano Genomics's ROE at -176.27%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $140.29 for Illumina and $0.23 for Bionano Genomics. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. Bionano Genomics's prices fluctuated between $0.20 and $2.27, with a yearly change of 1035.00%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.